From 3–5 June, Copenhagen becomes the meeting point for the in-house legal community as the ACC Europe Conference takes over the Tivoli Hotel & Congress Center for its 2026 edition — in media partnership with LegalcommunityGERMANY, Inhousecommunity, LegalcommunityCH,
Baer & Karrer advised Trusso Group on its strategic partnership with Ferax Treuhand, a Zurich-based audit and accounting firm specialising in the insurance sector.
Swiss law firm Bratschi has appointed Florian S. Jörg as its new Managing Partner, succeeding Sandra De Vito, while the firm's Board of Directors also undergoes significant changes with Claudio Bazzi taking over as
Homburger advised Raiffeisen Schweiz Genossenschaft on the issuance of its inaugural CHF 200 million 1.44% digital bail-in bond due 2033, to be traded on the SIX Swiss Exchange.
Bär & Karrer advised Alpine Select, an investment company listed on the SIX Swiss Exchange with domicile in Zug, as its shareholders approved the introduction of a statutory opting up provision at the ordinary
CMS Switzerland advised Rentokil Initial in connection with the acquisition of Zurich-based Hydroplant. The transaction was completed on 31 March 2026. The parties Hydroplant is a specialised provider of custom interior and exterior greening solutions, designing and
Schellenberg Wittmer advised OC Oerlikon on its placement of CHF 200 million senior unsecured bonds. OC Oerlikon, a specialist in surface technologies and advanced materials, has placed CHF 200 million 2.125% bonds due in 2031. Bank J. Safra Sarasin
Homburger advised Amazon.com on its inaugural Swiss franc bond offering, while Schellenberg Wittmer acted as Swiss legal counsel to the joint lead managers, in a six-tranche CHF issuance totalling CHF 2.82 billion. Deal details The
Kellerhals Carrard has advised Sequence SA on obtaining a FinTech Licence from the Swiss Financial Market Supervisory Authority (FINMA), placing the company among only five such licensed institutions in Switzerland.
Eli Lilly agreed to acquire LimmaTech Biologics — a Swiss clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases — for up to USD 780 m in cash, inclusive of an upfront payment and additional potential
